Claims
- 1. A chemical compound having the formula ##STR21## the possible stereochemically isomeric forms and the pharmaceutically acceptable acid-addition salts thereof, wherein:
- R is hydrogen, hydroxy or lower alkyloxy;
- R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;
- Alk is a lower alkanediyl radical;
- X is a member selected from the group consisting of --CH.sub.2 -- and --C(R.sup.2).dbd.C(R.sup.3)--, said R.sup.2 and R.sup.3 being each independently hydrogen or lower alkyl;
- A is a bivalent radical having the formula --CH.sub.2 --CH.sub.2 --CH.sub.2 -- and
- Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of pyridinyl, thienyl and phenyl, being optionally substituted with halo, hydroxy, lower alkyloxy, lower alkyl and trifluoromethyl.
- 2. A chemical compound according to claim 1 wherein Alk is an 1,2-ethanediyl radical.
- 3. A pharmaceutical composition in unit dosage form comprising per dosage unit a pharmaceutically acceptable carrier and an amount effective for treating patients suffering from psychosomatic disorders of at least one compound having the formula ##STR22## the possible stereochemically isomeric forms and the pharmaceutically acceptable acid-addition salts thereof, wherein:
- R is hydrogen, hydroxy or lower alkyloxy;
- R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;
- Alk is a lower alkanediyl radical;
- X is a member selected from the group consisting of --CH.sub.2 -- and --C(R.sup.2).dbd.C(R.sup.3)--, said R.sup.2 and R.sup.3 being each independently hydrogen or lower alkyl;
- A is a bivalent radical having the formula --CH.sub.2 --CH.sub.2 --CH.sub.2 -- and
- Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of pyridinyl, thienyl and phenyl, being optionally substituted with halo, hydroxy, lower alkyloxy, lower alkyl and trifluoromethyl.
- 4. A pharmaceutical composition according to claim 3 wherein Alk is an 1,2-ethanediyl radical.
- 5. A method of treating patients suffering from psychotropic disorders which comprises the systemic administration to said patients of a pharmaceutically acceptable amount of at least one compound having the formula ##STR23## the possible stereochemically isomeric forms and the pharmaceutically acceptable acid-addition salts thereof, wherein:
- R is hydrogen, hydroxy or lower alkyloxy;
- R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;
- Alk is a lower alkanediyl radical;
- X is a member selected from the group consisting of --CH.sub.2 -- and --C(R.sup.2).dbd.C(R.sup.3)--, said R.sup.2 and R.sup.3 being each independently hydrogen or lower alkyl;
- A is a bivalent radical having the formula --CH.sub.2 --CH.sub.2 --CH.sub.2 -- and
- Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of pyridinyl, thienyl and phenyl, being optionally substituted with halo, hydroxy, lower alkyloxy, lower alkyl and trifluoromethyl.
- 6. A method according to claim 5 wherein Alk is an 1,2-ethanediyl radical.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of our co-pending application Ser. No. 517,612, filed July 27, 1983, now U.S. Pat. No. 4,485,107, issued Nov. 27, 1984, which in turn is a continuation-in-part of application Ser. No. 438,079, filed Nov. 1, 1982, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4443451 |
Kennis et al. |
Apr 1984 |
|
4485107 |
Kennis et al. |
Nov 1984 |
|
4529727 |
Kennis et al. |
Jul 1985 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
37265 |
Oct 1981 |
EPX |
2005796 |
Jan 1977 |
JPX |
2406199 |
Aug 1975 |
NLX |
Non-Patent Literature Citations (2)
Entry |
Kennis et al., Chem. Abst. vol. 96--122814w, (1982). |
Kennis et al., Chem. Abst. vol. 98--16716x, (1983). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
517612 |
Jul 1983 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
438079 |
Nov 1982 |
|